Nicotinamide Riboside for Peripheral Artery Disease: The NICE Randomized Clinical Trial

Objective

To assess the effects of NR supplementation alone and in combination with resveratrol on the six-minute walk distance in individuals with peripheral artery disease (PAD).

Study Design

Randomized, double-blind, placebo-controlled, phase II study in 90 PAD patients

Dose

1000 mg NR alone or in combination with 125 mg resveratrol

Duration

6 months

Key Outcomes

  • NR supplementation significantly improved treadmill walking time and the six-minute walking distance (by 17.6 meters), a clinically meaningful change.

  • NR effectively improved walking performance in individuals with PAD, while resveratrol did not enhance the benefits of NR.

  • NR combined with resveratrol did not significantly improve the six-minute walk distance compared to placebo.

Clinical, Cardiovascular Health, Aging & LongevityANAD Staff